Skip to main content
×
Home

Unpacking the ‘black box’ of total pathogen burden: is number or type of pathogens most predictive of all-cause mortality in the United States?

  • A. M. SIMANEK (a1), J. B. DOWD (a2), A. ZAJACOVA (a3) and A. E. AIELLO (a4)
Summary
SUMMARY

A ‘black box’ paradigm has prevailed in which researchers have focused on the association between the total number of pathogens for which individuals are seropositive (i.e. total pathogen burden) and various chronic diseases, while largely ignoring the role that seropositivity for specific combinations of pathogens may play in the aetiology of such outcomes and consequently mortality. We examined the association between total pathogen burden as well as specific pathogen combinations and all-cause mortality in the United States. Data were from individuals aged ⩾25 years tested for cytomegalovirus (CMV), herpes simplex virus (HSV)-1, HSV-2 and Helicobacter pylori, with mortality follow-up to 31 December 2006 in the National Health and Nutrition Examination Survey (NHANES) III (N = 6522). We did not observe a statistically significant graded relationship between total pathogen burden level and all-cause mortality. Furthermore, compared to those seronegative for all four pathogens, the greatest statistically significant rate of all-cause mortality was for those CMV+/HSV-2+ (hazard ratio 1·95, 95% confidence interval 1·13–3·35) adjusting for age, gender, race/ethnicity, education level, body mass index (kg/m2) and smoking status. Interventions targeting prevention or treatment of particular pathogens may be more effective for reducing mortality than those focused solely on reducing overall pathogen burden.

Copyright
Corresponding author
* Author for correspondence: Dr A. E. Aiello, Professor of Epidemiology, Social Epidemiology Program Leader, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 2101C McGavran-Greenberg Hall, 135 Dauer Drive, Campus Box 7435, Chapel Hill, NC 27599-7435, USA. (Email: aaiello@unc.edu)
References
Hide All
1. O'Connor SM, Taylor CE, Hughes JM. Emerging infectious determinants of chronic diseases. Emerging Infectious Diseases 2006; 12: 10511057.
2. Izadi M, et al. Helicobacter species in the atherosclerotic plaques of patients with coronary artery disease. Cardiovascular Pathology 2012; 21: 307311.
3. Melnick JL, et al. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. Journal of Medical Virology 1994; 42: 170174.
4. Fraser NW, et al. Herpes simplex type 1 DNA in human brain tissue. Proceedings of the National Academy of Sciences USA 1981; 78: 64616465.
5. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 13111315.
6. Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circulation Research 2002; 90: 24.
7. Kountouras J, et al. Association between Helicobacter pylori infection and mild cognitive impairment. European Journal of Neurology 2007; 14: 976982.
8. Tarter KD, et al. Persistent viral pathogens and cognitive impairment across the lifecourse in the Third National Health and Nutrition Examination Survey. Journal of Infectious Diseases 2014; 209: 837844.
9. Ferreira AC, et al. Helicobacter and gastric malignancies. Helicobacter 2008; 13 (Suppl. 1): 2834.
10. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Research 2011; 157: 193203.
11. Epstein SE, et al. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20: 14171420.
12. Nazmi A, et al. The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis. BMC Public Health 2010; 10: 706.
13. Jackson L, et al. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 2009; 14: 108113.
14. Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132140.
15. Simanek AM, Dowd JB, Aiello AE. Persistent pathogens linking socioeconomic position and cardiovascular disease in the US. International Journal of Epidemiology 2009; 38: 775787.
16. Sealy-Jefferson S, et al. Antibody levels to persistent pathogens and incident stroke in Mexican Americans. PLoS ONE 2013; 8: e65959.
17. Aiello AE, et al. The influence of latent viral infection on rate of cognitive decline over 4 years. Journal of the American Geriatric Society 2006; 54: 10461054.
18. Aiello AE, et al. Persistent infection, inflammation, and functional impairment in older latinos. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences 2008; 63: 610618.
19. Jeon CY, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes Care 2012; 35: 520525.
20. Xia HH, et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. American Journal of Gastroenterology 2001; 96: 10391046.
21. Katan M, et al. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology 2013; 80: 12091215.
22. Miller GE, et al. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. American Journal of Cardiology 2005; 95: 317321.
23. Fernandez-Real J-M, et al. Burden of Infection and insulin resistance in healthy middle-aged men. Diabetes Care 2006; 29: 10581064.
24. Zhu J, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. American Journal of Cardiology 2000; 85: 140146.
25. Zhu J, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103: 4551.
26. Elkind MS, et al. Infectious burden and risk of stroke: the northern Manhattan study. Archives of Neurology 2010; 67: 3338.
27. Staras SA, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clinical Infectious Diseases 2006; 43: 11431151.
28. Schillinger JA, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976–1994. Sexually Transmitted Diseases 2004; 31: 753760.
29. U.S. Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey (NHANES III.: 1988–1994. NHANES III Second Laboratory File Documentation Series 11, No. 2A. Hyattsville, Maryland: Centers for Disease Control and Prevention, 1998.
30. Data Linkage Team. Comparative analysis of the NHANES III public-use and restricted-use linked mortality files: 2010 public-use data release. National Center for Health Statistics. March 2010. Hyattsville, Maryland (http://www.cdc.gov/nchs/data/datalinkage/nhanes3_mort_compare_2010_final.pdf).
31. SUDAAN. Example Manual, Release 10·0·1. Research Triangle Park, NC.: Research Triangle Institute, 2010.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate – a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B: Methodological 1995; 57: 289300.
33. Sun Y, et al. Herpes simplex virus type 2 infection is a risk factor for hypertension. Hypertension Research 2004; 27: 541544.
34. de Luis DA, et al. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. Diabetes Care 1998; 21: 11291132.
35. Thomas F, et al. Herpes simplex virus type 2 and cancer: a medical geography approach. Infection, Genetics and Evolution 2011; 11: 12391242.
36. Beydoun MA, et al. Helicobacter pylori seropositivity and cognitive performance among US adults: evidence from a large national survey. Psychosomatic Medicine 2013; 75: 486496.
37. Colberg-Poley AM, Isom HC, Rapp F. Reactivation of herpes simplex virus type 2 from a quiescent state by human cytomegalovirus. Proceedings of the National Academy of Sciences USA 1979; 76: 59485951.
38. Colberg-Poley AM, Isom HC, Rapp F. Involvement of an early human cytomegalovirus function in reactivation of quiescent herpes simplex virus type 2. Journal of Virology 1981; 37: 10511059.
39. Strachan DP, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study. British Medical Journal (Clinical Research Edition) 1999; 318: 10351039.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 2
Total number of PDF views: 31 *
Loading metrics...

Abstract views

Total abstract views: 281 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd November 2017. This data will be updated every 24 hours.